Tandem Diabetes (TNDM) EVP exercises 7,414 RSUs and sells 187 shares

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tandem Diabetes Care EVP & Chief Commercial Officer Mark David Novara reported several equity transactions. He exercised 7,414 Restricted Stock Units into the same number of common shares at a $0.00 conversion price, reflecting RSU vesting under the company’s 2023 Long-Term Incentive Plan.

To cover taxes on this vesting, 5,540 shares of common stock were withheld by Tandem Diabetes Care Inc. at $21.59 per share; the footnotes clarify that no shares were sold for this tax-withholding disposition. Novara then executed a separate open‑market sale of 187 common shares at $23.05 per share on the following day.

After these transactions, he directly holds 37,656 shares of common stock. The filing notes that the open‑market sale was carried out under a Rule 10b5‑1 trading plan that Novara adopted on December 4, 2025, indicating the sale was pre‑scheduled rather than a discretionary trade.

Insider Trade Summary

Net Seller: 187 shares ($4,310)

Net Sell 4 txns

Insider Novara Mark David

Role EVP & CHIEF COMMERCIAL OFFICER

Sold 187 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	187	$23.05	$4K
Exercise	Restricted Stock Unit	7,414	$0.00	--
Exercise	Common Stock	7,414	$0.00	--
Tax Withholding	Common Stock	5,540	$21.59	$120K

Holdings After Transaction: Common Stock — 37,656 shares (Direct); Restricted Stock Unit — 22,244 shares (Direct)

Footnotes (1)

Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025. Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

03/18/2026 - 04:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Novara Mark David

(Last)

(First)

(Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & CHIEF COMMERCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/16/2026		M		7,414	A	$0	43,383	D
Common Stock	03/16/2026		F⁽¹⁾		5,540	D	$21.59	37,843	D
Common Stock	03/17/2026		S⁽²⁾		187	D	$23.05	37,656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit⁽³⁾	⁽⁴⁾	03/16/2026		M			7,414	⁽⁵⁾	⁽⁵⁾	Common Stock	7,414	$0	22,244	D

Explanation of Responses:

1. Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

2. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025.

3. Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

4. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

5. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Remarks:

	/s/ Shannon M. Hansen, Attorney-in-Fact for Mark D. Novara	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did TNDM executive Mark David Novara report?

Mark David Novara reported exercising 7,414 RSUs into common stock, a tax-withholding disposition of 5,540 shares, and a separate open-market sale of 187 common shares, providing detail on both compensation-related vesting and a small planned share sale.

How many Tandem Diabetes Care (TNDM) shares does Novara hold after these Form 4 transactions?

After completing the RSU vesting, tax withholding, and a small open-market sale, Mark David Novara directly holds 37,656 shares of Tandem Diabetes Care common stock, according to the Form 4’s post-transaction ownership figures for his non-derivative holdings.

Was Novara’s sale of TNDM shares under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnotes state that the 187-share open-market sale was executed under a Rule 10b5-1 trading plan adopted by Mark David Novara on December 4, 2025, indicating the sale was pre-arranged rather than timed opportunistically.

What price did Novara receive for his open-market sale of TNDM common stock?

The Form 4 reports that Mark David Novara sold 187 shares of Tandem Diabetes Care common stock at a price of $23.05 per share, documenting both the small trade size and the specific per-share sale price for this transaction.

How were taxes handled on Novara’s vested Tandem Diabetes Care RSUs?

To satisfy tax withholding requirements on his RSU vesting, 5,540 Tandem Diabetes Care shares were withheld by the company at $21.59 per share. The footnotes clarify that these withheld shares were not sold into the market but applied to tax obligations.

What are the key details of Novara’s RSU vesting at Tandem Diabetes Care (TNDM)?

The RSUs were awarded on December 15, 2023 under Tandem Diabetes Care’s 2023 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock or cash, with vesting in tranches starting December 15, 2024 and continuing quarterly.